Tentative Approvals for: Par Pharm Inc

« Back to Dashboard

Par Pharm Inc Drugs with Tentative Approvals

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or try a Free Trial
Applicant	Generic Name	NDA	Strength	Dosage Form
Par Pharm Inc	colchicine	203976	0.6MG	TABLET;ORAL
Par Pharm Inc	milnacipran hydrochloride	205062	100MG	TABLET;ORAL
Par Pharm Inc	milnacipran hydrochloride	205062	12.5MG	TABLET;ORAL
Par Pharm Inc	milnacipran hydrochloride	205062	50MG	TABLET;ORAL
Par Pharm Inc	cyclobenzaprine hydrochloride	090864	30MG	CAPSULE, EXTENDED RELEASE; ORAL
Par Pharm Inc	dextromethorphan hydrobromide;quinidine sulfate	202993	20MG;10MG	CAPSULE;ORAL
Par Pharm Inc	vardenafil hydrochloride	204786	10MG	TABLET, ORALLY DISINTEGRATING;ORAL
Applicant	Generic Name	NDA	Strength	Dosage Form

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.